Evidence map›Paper›PMID 34389065›Full record

ArticleActa neuropathologica communications2021

Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.

Arnault Tauziède-Espariat, Aurore Siegfried, Yvan Nicaise, Thomas Kergrohen, Philipp Sievers, Alexandre Vasiljevic, Alexandre Roux, Edouard Dezamis, Chiara Benevello, Marie-Christine Machet and 25 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. ZFTA::YAP1-rearranged ependymoma: is still ZFTA or already YAP?Acta neuropathologica communications · 2026
    Article
  3. Clinical, surgical, and molecular features of pediatric supratentorial ependymomas: a single-institution experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Article
  4. A brief history of ependymoma.Neuro-oncology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Long-term prognosis and treatment outcomes in infantile and neonatal brain tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 17 institutions in 2 countries.

Arnault Tauziède-Espariat *Department of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France. a.tauziede-espariat@ghu-paris.fr.
Aurore Siegfried *Department of Pathology, Toulouse University Hospital, Toulouse, France.
Yvan NicaiseINSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Thomas KergrohenU981, Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
Philipp SieversDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Alexandre VasiljevicDepartment of Pathology and Neuropathology, GHE, Hospices Civils de Lyon, Lyon, France.
Alexandre RouxUniversité de Paris, Paris, France.
Edouard DezamisDepartment of Neurosurgery, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, France.
Chiara BenevelloDepartment of Neurosurgery, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, France.
Marie-Christine MachetDepartment of Pathology, Tours Hospital, Tours, France.
Sophie MichalakDepartment of Pathology, Angers Hospital, Angers, France.
Chloe PuiseuxDepartment of Oncology, Pontchaillou Hospital, Rennes, France.
Francisco Llamas-GutierrezDepartment of Oncology, Pontchaillou Hospital, Rennes, France.
Pierre LeblondInstitute of Pediatric Hematology and Oncology (IHOPe), Centre Léon Bérard, Lyon, France.
Franck BourdeautDepartment of Pediatric Oncology, Institut Curie, Paris, France.
Jacques GrillDepartment of Child and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Christelle DufourDepartment of Child and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Léa Guerrini-RousseauDepartment of Child and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Samuel AbbouDepartment of Child and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Volodia Dangouloff-RosUniversité de Paris, Paris, France.
Nathalie BoddaertUniversité de Paris, Paris, France.
Raphaël SaffroyDepartment of Biochemistry and Oncogenetics, Paul Brousse Hospital, 94804, Villejuif, France.
Lauren HastyDepartment of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France.
Ellen WahlerDepartment of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France.
Mélanie PagèsDepartment of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France.
Felipe AndreiuoloDepartment of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France.
Emmanuèle LechaptDepartment of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France.
Fabrice ChrétienDepartment of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France.
Thomas BlauwblommeDepartment of Pediatric Neurosurgery, Necker Hospital, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Kévin BeccariaDepartment of Pediatric Neurosurgery, Necker Hospital, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Johan PalludInstitut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France.
Stéphanie PugetDepartment of Pediatric Neurosurgery, Necker Hospital, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Emmanuelle Uro-Coste *Department of Pathology, Toulouse University Hospital, Toulouse, France.
Pascale Varlet *Department of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France.
RENOCLIP-LOC, the BIOMECA (Biomarkers for Ependymomas in Children, Adolescents) consortium
Centre Hospitalier Sainte-Anne · FRInserm · FRUniversité Paris Cité · FRCentre de Recherche en Cancérologie de Toulouse · FRDélégation Paris 5 · FRHôpital Pontchaillou · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Tours · FRHeidelberg University · DEHôpital Paul-Brousse · FRHospices Civils de Lyon · FRInstitut Curie · FRInstitut d’Hématologie et d’Oncologie Pédiatrique · FRInstitut Gustave Roussy · FRSorbonne Paris Cité · FRUniversité d'Angers · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cIMPACT-NOW Update 7 has replaced the WHO nosology of "ependymoma, RELA fusion positive" by "Supratentorial-ependymoma, C11orf95-fusion positive". This modification reinforces the idea that supratentorial-ependymomas exhibiting fusion that implicates the C11orf95 (now called ZFTA) gene with or without the RELA gene, represent the same histomolecular entity. A hot off the press molecular study has identified distinct clusters of the DNA methylation class of ZFTA fusion-positive tumors. Interestingly, clusters 2 and 4 comprised tumors of different morphologies, with various ZFTA fusions without involvement of RELA. In this paper, we present a detailed series of thirteen cases of non-RELA ZFTA-fused supratentorial tumors with extensive clinical, radiological, histopathological, immunohistochemical, genetic and epigenetic (DNA methylation profiling) characterization. Contrary to the age of onset and MRI aspects similar to RELA fusion-positive EPN, we noted significant histopathological heterogeneity (pleomorphic xanthoastrocytoma-like, astroblastoma-like, ependymoma-like, and even sarcoma-like patterns) in this cohort. Immunophenotypically, these NFκB immunonegative tumors expressed GFAP variably, but EMA constantly and L1CAM frequently. Different gene partners were fused with ZFTA: NCOA1/2, MAML2 and for the first time MN1. These tumors had epigenetic homologies within the DNA methylation class of ependymomas-RELA and were classified as satellite clusters 2 and 4. Cluster 2 (n = 9) corresponded to tumors with classic ependymal histological features (n = 4) but also had astroblastic features (n = 5). Various types of ZFTA fusions were associated with cluster 2, but as in the original report, ZFTA:MAML2 fusion was frequent. Cluster 4 was enriched with sarcoma-like tumors. Moreover, we reported a novel anatomy of three ZFTA:NCOA1/2 fusions with only 1 ZFTA zinc finger domain in the putative fusion protein, whereas all previously reported non-RELA ZFTA fusions have 4 ZFTA zinc fingers. All three cases presented a sarcoma-like morphology. This genotype/phenotype association requires further studies for confirmation. Our series is the first to extensively characterize this new subset of supratentorial ZFTA-fused ependymomas and highlights the usefulness of ZFTA FISH analysis to confirm the existence of a rearrangement without RELA abnormality.

Indexed as

AdolescentAdultChildChild, PreschoolDNA MethylationEpendymomaFemaleGene FusionGenotypeGlial Fibrillary Acidic ProteinHumansInfantMaleNeural Cell Adhesion Molecule L1NF-kappa BNuclear Receptor Coactivator 1GFAP protein, humanGlial Fibrillary Acidic ProteinL1CAM protein, humanMAML2 protein, humanMN1 protein, humanNCOA1 protein, humanNCOA2 protein, humanNeural Cell Adhesion Molecule L1NF-kappa BNuclear Receptor Coactivator 1Nuclear Receptor Coactivator 2ProteinsRELA protein, humanTrans-ActivatorsTranscription Factor RelATranscription FactorsTumor Suppressor ProteinsZFTA protein, humanClustersDNA-methylationEpendymomaRELAZFTA

Identifiers

PMID34389065
PMCPMC8362233
OpenAlexW3192870135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.